Previous Section
Clinical Trials
1. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
- Author
- Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinkothe T; Stutzer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A;
- Institution
- Department of Hematology and Oncology, University of Cologne, Cologne, Germany.
- Journal
- J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6.
- Abstract URL
- Click here to view abstract
2. Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study.
- Author
- Delgado J; Thomson K; Russell N; Ewing J; Stewart W; Cook G; Devereux S; Lovell R; Chopra R; Marks DI; Mackinnon S; Milligan DW;
- Institution
- Department of Hematology, Birmingham Heartlands Hospital, Birmingham, B9 5SS, United Kingdom.
- Journal
- Blood. 2006 Feb 15;107(4):1724-30. Epub 2005 Oct 20.
- Abstract URL
- Click here to view abstract
3. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.
- Author
- Eichhorst BF; Busch R; Hopfinger G; Pasold R; Hensel M; Steinbrecher C; Siehl S; Jager U; Bergmann M; Stilgenbauer S; Schweighofer C; Wendtner CM; Dohner H; Brittinger G; Emmerich B; Hallek M;
- Institution
- Department of Internal Medicine I, University of Cologne, Kerpener Str 62, D-50924 Koln, Germany.
- Journal
- Blood. 2006 Feb 1;107(3):885-91. Epub 2005 Oct 11.
- Abstract URL
- Click here to view abstract
4. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy.
- Author
- Dungarwalla M; Evans SO; Riley U; Catovsky D; Dearden CE; Matutes E;
- Institution
- Journal
- Haematologica. 2008 Mar;93(3):475-6.
- Abstract URL
- Click here to view abstract
5. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.
- Author
- O'Brien SM; Cunningham CC; Golenkov AK; Turkina AG; Novick SC; Rai KR;
- Institution
- M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030-7305, USA. sobrien@mdanderson.org
- Journal
- J Clin Oncol. 2005 Oct 20;23(30):7697-702. Epub 2005 Sep 26.
- Abstract URL
- Click here to view abstract
6. Cyclophosphamide followed by fludarabine for untreated chronic lymphocytic leukemia: a phase II SWOG TRIAL 9706.
- Author
- Hussein MA; Gundacker H; Head DR; Elias L; Foon KA; Boldt DH; Dobin SM; Dakhil SR; Budd GT; Appelbaum FR;
- Institution
- Cleveland Clinic Foundation, Myeloma Program, Cleveland, OH, USA. pubs@swog.org
- Journal
- Leukemia. 2005 Nov;19(11):1880-6.
- Abstract URL
- Click here to view abstract
7. Phase I trial of nelarabine in indolent leukemias.
- Author
- Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO Jr; Lerner S; Plunkett W; Keating MJ;
- Institution
- Department of Experimental Therapeutics, Box 71, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. vgandhi@mdanderson.org
- Journal
- J Clin Oncol. 2008 Mar 1;26(7):1098-105.
- Abstract URL
- Click here to view abstract
8. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
- Author
- Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA;
- Institution
- Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA. jhainsworth@tnonc.com
- Journal
- Cancer. 2008 Mar 15;112(6):1288-95.
- Abstract URL
- Click here to view abstract
9. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
- Author
- Catovsky D; Richards S; Matutes E; Oscier D; Dyer MJ; Bezares RF; Pettitt AR; Hamblin T; Milligan DW; Child JA; Hamilton MS; Dearden CE; Smith AG; Bosanquet AG; Davis Z; Brito-Babapulle V; Else M; Wade R; Hillmen P;
- Institution
- Section of Haemato-Oncology, Institute of Cancer Research, Sutton, UK. daniel.catovsky@icr.ac.uk
- Journal
- Lancet. 2007 Jul 21;370(9583):230-9.
- Abstract URL
- Click here to view abstract
10. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
- Author
- Robak T; Smolewski P; Cebula B; Grzybowska-Izydorczyk O; Blonski JZ;
- Institution
- Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland. robaktad@csk.umed.lodz.pl
- Journal
- Eur J Haematol. 2007 Aug;79(2):107-13.
- Abstract URL
- Click here to view abstract
Next: Immunotherapy
